A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory B-cell Malignancies And Advanced Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically-proven B cell malignancies or relapsed, refractory B-cell non-Hodgkin lymphoma or relapsed, refractory chronic lymphocytic leukemia requiring therapy or metastatic breast cancer (including ER/PR positive or negative, Her-2 positive and negative, triple negative). 2) For multiple myeloma, relapsed or progressive on or after treatment with at least three prior therapies. For ovarian cancer, progressive after treatment with at least prior platinum-based chemotherapy. For soft tissue sarcoma, treated with at least one line of chemotherapy. Recurrent metastatic or locally advanced pancreatic cancer after first line chemotherapy and positive biomarker status (back-fill patients only). 3) Histologically-proven solid tumor meeting the following criteria: patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies).

You may not be eligible for this study if the following are true:

  • 1) Known history of HIV and known history of viral hepatitis B unless HBV viral load is below the limit of quantification and off viral suppressive therapy. 2) Myocardial infarction or stroke within 6 months. 3) Uncontrolled hypertension (systolic blood pressure (SBP) > 160 or diastolic blood pressure (DBP) >100 on maximal medical therapy).


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.